Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine

Eligibility Criteria

• 1. Age: 26-84
• 2. Sex: Both males and females will be included
• 3. Diagnosis of dopamine receptor-blocker induced tardive dyskinesia according to the DSM-5 criteria: "involuntary athetoid or choreiform movements lasting at least a few weeks, developing in association with the use of a neuroleptic medication for at least a few months, and persisting beyond 4-8 weeks"
• 1. Patients with unstable psychiatric status defined as having a total score on BPRS of 50 or higher
• 2. Patients who have suicidal or homicidal ideation, intent, or plan or viewed as having a significant risk of suicidal or violent behavior;
• 3. Patients with cognitive impairment as defined by a score of 24 or less on the MMSE
• 4. Patients with current diagnosis of alcohol or substance use disorder made according to DSM-5 criteria
• 5. Patients with clinically significant unstable medical condition defined as follows: a comorbid abnormal movement disorder more prominent than tardive dyskinesia (e.g., parkinsonism, akathisia, truncal dystonia), a score of greater than 2 on two or more items of the Simpson-Angus Scale, or a history of neuroleptic malignant syndrome.
• 6. Patients previously treated with Valbenazine or any other medication specifically indicated for tardive dyskinesia
• 7. Patients currently taking strong CYP3A4 inducers, dopamine agonists, MAO inhibitors, stimulants, and/or VMAT2 inhibitors
• 8. Patients with congenital long QT syndrome or arrhythmias associated with prolonged QT interval
• 9. Patients with risk factors for prolonged QT such as electrolyte abnormalities (hypokalemia, hypocalcemia, hypomagnesemia), anorexia nervosa, diuretic use, certain heart conditions, and other medical conditions
• 10. Patients tested positive for Coronavirus Covid-19
• 11. Patients with impaired decision-making capacity
• 12. Institutionalized individuals
• 13. Prisoners